High-Dose Omalizumab versus Ligelizumab for the Treatment of Chronic Spontaneous Urticaria: Do Not We Need a Head-To-Head Comparison?

Alexandros G.Sfakianakis shared this article with you from Inoreader High-Dose Omalizumab versus Ligelizumab for the Treatment of Chronic Spontaneous Urticaria: Do Not We Need a Head-To-Head Comparison? Μέσω IAA : Last 20 articles Int Arch Allergy Immunol View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.